… The presence of wild-type FLT3, which is sensitive to FLT3 ligand and relatively resistant
to … to have promising antileukemia activity both in vitro and in FLT3-ITD murine models [39]. …

… One of the critical issues of treatment with FLT3 inhibitors in FLT3-mutated AML is drug
resistance. FLT3 ligand (FL) represents a mechanism of resistance to FLT3 inhibitors, including …

… leukemia cells and normal hematopoietic stem cells. The activation of FLT3 is initiated by the
binding of the FLT3 ligand … in the AML cell line and in vivo anticancer efficacy in a xenograft …

… changes within FLT3 result in constitutive activation without stimulation of the FLT3 ligand
(FL… We report in vitro anti-leukemic activity of LT-171-861 that is as potent as that of AC220 and …

… Antileukemic activity of quizartinib in xenograft models of midostaurin-… on the antileukemic
activity of FLT3 inhibitors in the mouse xenograft model… signaling, independent of FLT3 ligand. …

… (4) When the FLT3 ligand (FL) binds the extracellular domain, FLT3 dimerizes and is …
antileukemic activity in mice xenografted with FLT3-ITD-D835Y cells, extending the OS of mice…

… and is activated by FLT3 ligand (FL). … mouse models, gilteritinib decreased FLT3
phosphorylation levels along with its downstream targets supporting single-agent anti-leukemic …

… antileukemic effect of HSCT is driven by recognition and elimination of allogeneic antigens
on chemoresistant leukemic … with or without 10 ng/mL soluble FLT3 ligand (16) for 48 hours. …

… Moreover, the enhanced antileukemic activity by quizartinib and dexamethasone … and
xenograft mouse models. Collectively, our study indicates that the combination of FLT3 inhibitors …

… These first-generation inhibitors lack specificity for FLT3 and perform antileukemia efficacy
… and FLT3 may contribute to the antileukemia therapy, particularly drug resistance after FLT3 …